Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention

Risk of death is particularly high in patients with a previous history of arterial occlusive events (AOEs) and the probability for a recurrent event is around 20%. Little is known about recurrent AOE and the role of secondary prevention in patients with Chronic Myeloid Leukemia (CML) with previous AOE, treated with second- and third-generation tyrosine kinase inhibitors (2ndG/3rdG TKIs), nilotinib, dasatinib, bosutinib and ponatinib.

Source: International Journal of Cardiology - April 16, 2019 Category: Cardiology Authors: Giovanni Caocci, Olga Mulas, Massimiliano Bonifacio, Elisabetta Abruzzese, Sara Galimberti, Ester Maria Orlandi, Alessandra Iurlo, Mario Annunziata, Luigiana Luciano, Fausto Castagnetti, Antonella Gozzini, Fabio Stagno, Gianni Binotto, Patrizia Pregno, Fr Tags: Short communication Source Type: research